|
Assistant Research Scientist
Selected publications
Sinha P, Parker KH, Horn L, and Ostrand-Rosenberg S. Tumor-induced myeloid-derived suppressor cell function is independent of IFNg and IL4Rα. European Journal of Immunology August 2012; 42(8): 2052–2059.
[Abstract]
Ostrand-Rosenberg S, Sinha P, Chornoguz O, and Ecker C. Regulating the Suppressors: Apoptosis and inflammation govern the survival of tumor-induced Myeloid-derived Suppressor Cells (MDSC). Cancer Immunol Immunother Aug 2012; 61(8): 1319-25.
[Abstract] Ostrand-Rosenberg S, Sinha P, Beury DW, and Clements VK. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhance tumor-induced immune suppression. Seminars in Cancer Biology 2012 Aug; 22(4): 275-81. [Abstract] Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, and Ostrand-Rosenberg S. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response
to T cell-expressed FasL. Blood Published online before print March 30, 2011, doi: 10.1182/blood-2010-11-321752. [Abstract] [Text] [PDF] Chornoguz O, Grmai L, Sinha P, Artemenko K, Zubarev RA, and Ostrand-Rosenberg S. Proteomic Pathway Analysis Reveals Inflammation Increases Myeloid-Derived Suppressor Cell Resistance to Apoptosis. Mol Cell Proteomics, 2011 Mar;10(3):M110.002980. Epub 2010 Dec 29.[Abstract] Srivastava MK, Sinha P, Clements VK, Rodriguez P, and Ostrand-Rosenberg S. Myeloid-derived Suppressor Cells Inhibit T Cell Activation by Depleting Cystine and Cysteine. Cancer Research 2010; 70: 68-77.[Abstract] [Text] [PDF] Hanson EM, Clements VK, Sinha P, Ilkovitch D, and Ostrand-Rosenberg S. Myeloid-derived Suppressor Cells Down-regulate L-Selectin Expression on CD4+ and CD8+ T Cells. J Immunology 2009; 183: 937-944. [Abstract] [Text] [PDF] Ostrand-Rosenberg S and Sinha P. Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol. 2009 Apr 15; 182(8): 4499-506. [Abstract] [Text] [PDF] Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S. Inflammation Enhances Myeloid-derived Suppressor Cell Cross-talk By Signaling Through Toll-like Receptor 4. J Leukoc Biol. 2009; 85: 996-1004.[Abstract] [Text] [PDF] Sinha P, Okoro C, Foell D, FreezeHH, Ostrand-Rosenberg S, and Srikrishna G. Pro-inflammatory S100 Proteins Regulate the Accumulation of Myeloid-derived Suppressor Cells. Journal of Immunology 2008; 181(7):4666-75.[Abstract] [Text] [PDF] Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, Nguyen M, Olsson A, Nawroth PP, Bierhaus A, Varki N, Kronenberg M, Freeze HH, Srikrishna G. (2008). RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis, 29:2035-43.[Abstract] [Text] [PDF] Sinha P, Clements VK, Bunt SK, Steven M. Albelda and Ostrand-Rosenberg S. Cross-talk Between Myeloid-derived Suppressor Cells and Macrophages Subverts Tumor Immunity Towards a Type 2 Response. J. Immunology 2007; 179: 977-983.[Abstract] [Text] [PDF] Sinha P, Clements VK, Fulton AM, and Ostrand-Rosenberg S. Prostaglandin E2 Promotes Tumor Progression By Inducing Myeloid-derived Suppressor Cells. Cancer Rresearch May 1st 2007; 67: 4507-13.
[Abstract] [Text] [PDF] Sinha P, Snyder J, Kim E.Y, and Moudgil K.D. The major histocompatibility complex haplotypes dictate and the background genes fine-tune the dominant versus the cryptic response profile of a T cell determinant within a native antigen: relevance to disease susceptibility and vaccination. Scan J Immunol 2007; 65(2): 158-65.[Abstract] [Text] [PDF] Bunt SK, Hanson EM, Sinha P, Srivastava MK, Clements VK, and Ostrand-Rosenberg S. Tumor associated myeloid-derived suppressor cells. In: Cancer Immunotherapy: Immune Suppression and Tumor Growth. (Eds: George Prendergast and Elizabeth Jaffee. Chapter 17, p. 309. Elsevier Inc. June 2007. Bunt SK, Sinha P, Clements VK, Leips J and Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitates tumor progression. J. Immunology 2006; 176 (1): 284-290.[Abstract] [Text] [PDF] Sinha P, Clements VK and Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Research 2005: 65 (24): 11743-11751.[Abstract] [Text] [PDF] Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, Hayakawa Y, Godfrey DI, Ostrand-Rosenberg S, Smyth MJ and Berzofsky JA. A non-classical non-Va14Ja18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Experimental Medicine 2005; 202: 1627-1633.[Abstract] [Text] [PDF] Sinha P, Clements VK, Miller S and Ostrand-Rosenberg S. Tumor immunity: A balancing act between T cell activation, macrophage activation and tumor induced immunosuppression. Cancer Immunol Immunother. 2005; 54 (11): 1137-1142.[Abstract] [Text] [PDF] Sinha P, Clements VK and Ostrand-Rosenberg S. Reduction of Myeloid Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic disease. J. Immunology 2005; 174 (2): 636-645.[Abstract] [Text] [PDF] Sinha P, Chi H, Kim HR, Clausen BE, Pederson B, Sercarz EE, Forster I and Moudgil KD. Mouse lysozyme-M knockout mice reveal how the self-determinant hierarchy shapes the T cell repertoire against this circulating self antigen in wild-type mice. J. Immunology 2004: 173; 1763-1771.[Abstract] [Text] [PDF] Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA and Ostrand-Rosenberg S. Surgical Removal of Primary Tumor Reverses Tumor-induced Immunosuppression Despite the Presence of Metastatic Disease. Cancer Research 2004: 64; 2205-2211.[Abstract] [Text] [PDF] Ostrand-Rosenberg S, Sinha P, Clements VK, Dissanayake SK, Miller S, Davis C, Danna EA. Signal Transducer and Activator of Transcription 6 (Stat6) and CD1: Inhibitors of Immunosurveillance Against Primary Tumors and Metastatic Disease. Cancer Immunol Immunother. 2004: 53: 86-91.[Abstract] [Text] [PDF] Ostrand-Rosenberg S, Sinha P, Danna EA, Miller S, Davis C, Dissanayake SK. Antagonists of Tumor-Specific Immunity: Tumor-Induced Immune Suppression and Host Genes that Co-opt the Anti-tumor Immune Response. In Immunology of Breast Cancer, Breast Disease. Ed. WZ Wei and D.Lopez. IOS Press, Amsterdam, The Netherlands, 2004; 20: 127-35[Abstract] Sinha P and Ray P.K. Functional dichotomy of a 20-mer and 16-mer peptide derived from staphylococcus aureus protein-A: Importance of aminoacid sequence. Immunopharmacol and Immunotoxicol 2002: 24 (2); 199-210.[Abstract] Sinha P, Sengupta J and Ray P.K. Functional mimicry of Protein A of Staphylococcus aureus by a proteolytically cleaved fragment. Biochem Biophys Res Commun 1999. Jun 24; 260(1): 111-116. [Abstract] Das T, Sa G, Sinha P and Ray P.K. Induction of cell proliferation and apoptosis: Dependence on the dose of the inducer. Biochem Biophys Res Commun 1999. Jun 24; 260 (1): 105-110[Abstract] Sinha P, GhoshAK, Das T, Sa G and Ray PK. Protein A of S aureus evokes Th1 type response in mice. Immunol Letters 1999; 67: 157-165[Abstract] Sinha P, Sengupta J, Ray PK. A minimized Fc binding peptide from protein A induces immunocyte proliferation and evokes Th1-type response in mice. Biochem Biophys Res Commun 1999 Apr 29;258(1):141-7[Abstract] Ghosh AK, Sinha P, Das T, Sa G, Ray PK. S. aureus superantigen protein A expands CD4(+)/CD8(+)/CD19(+)/CD34(+) cells in mice: a potential immunorestorer. Biochem Biophys Res Commun 1999 Mar 5;256(1):142-6[Abstract] Sengupta J, Sinha P, Mukhopadhyay C, Ray PK. Molecular modeling and experimental approaches toward designing a minimalist protein having Fc-binding activity of Staphylococcal protein A. Biochem Biophys Res Commun 1999 Mar 5;256(1):6-12[Abstract] Ray P.K., Das T., Subbulakshmi V, Ghosh A.K. Sa G, Sinha P. and Sengupta J. Immunopharmacologic Modulation of host response to increase therapeutic index of drugs. Immunopharmacology: stratigies for immunotherapy (S.N Upadhyay Ed.), Narosa Publishing House, New Delhi. 1999 Ray P.K., Goenka S., Das T., Sa Gaurisankar, Sinha P. and Srivastava M. Role of Nitric oxide in Immune function and amelioration of toxicity and carcinogenicity of drugs and chemicals 1997. In Biological oxidants and Antioxidants : Molecular Mechanism and health effects (Editor Huaug AOCS Press) Chap 7 : 42-53 Sinha P, Naik S, Ayyagari A, Naik SR. Isoenzyme and molecular characterization of Entamoeba histolytica and Entamoeba dispar isolates from symptomatic and asymptomatic subjects. Indian J Gastroenterol 1999 Jan-Mar;18(1):18-21. [Abstract] Sinha P., Ghosal U.C., Choudhuri G., Naik S., Ayyagari A. and Naik S.R. Does Entamoeba histolytica cause irritablele bowel syndrome? Indian J Gastroenterol 1997; 16: 130-33.[Abstract] Sinha P., Naik S., Ayyagari A and Naik SR. The effect of in vitro bacterial association on virulence of Entamoeba histolytica. Indian J. Med. Res. 1997; 105 : 266-70. [Abstract]
|
